Johnson and Johnson: Nipocalimab is the First and Only Investigational Therapy Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Adults Living With Moderate-to-Severe Sjogren's Disease
November 12, 2024
November 12, 2024
NEW BRUNSWICK, New Jersey, Nov. 12 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
The Breakthrough Therapy Designation (BTD) for investigational nipocalimab in Sjogren's disease, a prevalent autoantibody disease with no approved advanced therapies, is supported by results from the Phase 2 DAHLIAS study
A greater than 70 percent relative improvement in systemic disease activity at Week 24 was demonstrated in study participants on av . . .
* * *
The Breakthrough Therapy Designation (BTD) for investigational nipocalimab in Sjogren's disease, a prevalent autoantibody disease with no approved advanced therapies, is supported by results from the Phase 2 DAHLIAS study
A greater than 70 percent relative improvement in systemic disease activity at Week 24 was demonstrated in study participants on av . . .